Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -8 of 8 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 6/6/2008 First Published: 6/2/2006


1.		Phase II Study of Combination Chemotherapy, Radiotherapy, and/or Surgery in Patients With High-Risk Renal Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				30 and under				NCI				COG-AREN0321 AREN0321, NCT00335556


2.		Bevacizumab(Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				SCRI GU 32 AVF3673s, NCT00323739

Last Modified: 11/17/2006 First Published: 10/21/2006


3.		Phase II Study of Nonmyeloablative Lymphodepleting Chemotherapy Comprising Cyclophosphamide and Fludarabine Phosphate Followed By Anti-p53 T-Cell Receptor-Transduced Peripheral Blood Lymphocytes and High-Dose Aldesleukin in Patients With Metastatic Cancer That Overexpresses p53

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				NCI-07-C-0003 NCI-P6850, NCT00393029


4.		Phase 2 Study in Patients With MiT Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				13 and over				Pharmaceutical / Industry				ARQ 197-204 NCT00557609


5.		R1507 in Patients With Recurrent or Refractory Sarcomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				12 and over				Other				2007-0515 NCT00615680

Last Modified: 5/19/2008 First Published: 2/19/2008


6.		Phase I Study of Bortezomib and Gemcitabine in Older Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				70 and over				NCI				UMN-2006LS040 UMN-2006LS040, UMN-X05227, NCT00620295


7.		Comparison of Immune Response Following Surgical Management of Renal Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Natural history/Epidemiology, Treatment				Active				18 and over				Other				IRB3 021-2005 NCT00289146


8.		Respiratory Tumor and Normal Tissue Motion

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Natural history/Epidemiology, Treatment				Active				Not specified				Other				2003-0962 NCT00415675

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute